search
Back to results

Evaluating a Novel Internet Intervention for Persons With Epilepsy and Depression (ENCODE)

Primary Purpose

Depression, Epilepsy

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Desiconnect
CAU
Sponsored by
Gaia AG
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age at least 18 years
  • diagnosis of active epilepsy (that is, at least one epileptic seizure within the past 10 years or taking antiseizure medicines within the past five years)
  • current depressive disorder (either major depressive disorder or dysthymic disorder, as determined by telephone interview with the MINI Neuropsychiatric Interview)
  • no current antidepressant medication, or current antidepressant medication but no changes in dosage for at least one month prior to study inclusion (medication changes after study inclusion are permitted, given the pragmatic design of the trial)
  • currently at least moderate self-reported depressive symptom severity, as operationalized by a score of at least 10 on the PHQ-9, a cut-off score that has been well validated
  • ability to speak and read German
  • access to the internet and personal possession of an appropriate device on which the internet-based intervention can be used regularly (e.g., smartphone, computer, laptop)
  • expressed motivation to participate in the trial and use an internet-based intervention to acquire skills and knowledge that may aid in the amelioration of depression symptoms

Exclusion Criteria:

  • current psychotherapy
  • other known major psychiatric disorder, such as bipolar disorder, schizophrenia or another psychotic disorder, or borderline personality disorder (based on the MINI interview)
  • acute suicidality (that is, intention or plan to commit suicide, as assessed with the respective module of the MINI interview)
  • newly prescribed antidepressant medication or change in antidepressant medication dosage in month prior to study inclusion

Sites / Locations

  • University Medical Center Hamburg-Eppendorf (UKE), Department of Psychiatry and Psychotherapy

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Desiconnect

Care-as-Usual (CAU) / wait list

Arm Description

Desiconnect is an Internet-administered intervention developed for persons with epilepsy and elevated depression symptoms.

In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Desiconnect three months post-baseline (i.e., wait list with respect to Desiconnect access).

Outcomes

Primary Outcome Measures

Severity of depressive symptoms, measured by Patient Health Questionnaire - 9 items (PHQ-9)
Self-report depression symptom severity measure

Secondary Outcome Measures

NDDIE (Neurological Disorders Depression Inventory for Epilepsy)
Epilepsy-specific self-report measure of depression symptom severity
GAD-7 (Generalized Anxiety Disorder Questionnaire)
Self-report anxiety symptom severity measure
DASS-21 (Depression and Anxiety Scales)
Self-report measure of anxiety, depression, and stress symptoms
WSAS (Work and Social Adjustment Scale)
Self-report measure of depression-related psychosocial impairment
Subjective usefulness of the program
Individually designed self-report items
INEP (Inventory for the Assessment of Negative Effects of Psychotherapy)
Adapted self-report measure assessing potential negative effects of the Internet intervention
PESOS
Self-report measure of epilepsy symptoms
LSSS (Liverpool Seizure Severity Scale)
Self-report measure of epilepsy symptoms
QOLIE-10 (Health-related Quality of Life)
Self-report measure of health-related quality of life
ESMS (Epilepsy Self-Management Scale)
Self-report measure of epilepsy self-management practices

Full Information

First Posted
June 1, 2016
Last Updated
July 31, 2019
Sponsor
Gaia AG
Collaborators
Universitätsklinikum Hamburg-Eppendorf
search

1. Study Identification

Unique Protocol Identification Number
NCT02791724
Brief Title
Evaluating a Novel Internet Intervention for Persons With Epilepsy and Depression
Acronym
ENCODE
Official Title
Evaluating a Novel Cognitive-Behavioral Online Depression Intervention for Persons With Epilepsy (Desiconnect): Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
June 2016 (undefined)
Primary Completion Date
February 2018 (Actual)
Study Completion Date
February 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gaia AG
Collaborators
Universitätsklinikum Hamburg-Eppendorf

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The trial aims to evaluate the effectiveness of a novel internet intervention (Desiconnect), which was designed to introduce relevant cognitive-behavioral therapy (CBT) techniques to Persons with Epilepsy (PwE) and comorbid depression. Therefore, 200 PwE and a current depressive disorder (major depressive disorder or dysthymic disorder) will be recruited and randomized to two groups: (1) a control group, in which they may engage with any epilepsy treatment (Care-as-Usual, CAU) and receive access to Desiconnect after a delay of three months (i.e., CAU/wait list control group), or (2) to a treatment group that immediately receives six-month access to Desiconnect and may also use CAU. The primary outcome measure is the depression scale of the Patient Health Questionnaire (PHQ-9), collected at three months post-baseline.
Detailed Description
Depression is common among persons with epilepsy (PwE), affecting roughly one in three individuals, and its presence is associated with personal suffering, impaired quality of life, and worse prognosis. Despite the availability of effective treatments, depression is often overlooked and treated inadequately in PwE, in part because of concerns over drug interactions. Previous studies strongly suggest that cognitive behavioral therapy (CBT) can help alleviate depression in PwE, but CBT is not always available to patients. Internet-administered psychological interventions are easily accessible and might complement antidepressant medication or psychotherapy, and preliminary evidence suggests that such interventions can be effective. However, no trial has yet examined whether a CBT-based internet intervention designed to meet the needs of PwE can achieve sustained reductions in depression and related symptoms, such as anxiety, when offered as adjunct to treatment as usual. The Internet-based intervention evaluated in this trial was designed with the aim of conveying evidence-based psychotherapeutic techniques, gleaned primarily from CBT, to PwE over a period of 180 days. The intervention focuses on identifying and challenging cognitions that trigger or sustain depression and anxiety, increasing activities that are likely to reduce depression and anxiety, practicing relaxation and stress management exercises and increasing mindfulness skills. The program is based on general CBT and other evidence-based psychotherapeutic techniques that have been shown to be helpful for patients suffering from depression (and ideally, that have been shown to be helpful among PwE). Furthermore, program content addresses other issues in disease self-management, including lifestyle habits (e.g., nutrition, exercise) and medication adherence. The delivery and training of content is continuously individualized to match users' preferences and needs, based on responses within the program. The intervention is delivered via the Internet and protected by individually assigned passwords. This randomized controlled trial will include 200 participants with epilepsy and a current depressive disorder, along with currently at least moderately elevated depression. Participants will be recruited from various settings, including epilepsy treatment clinics, outpatient treatment centers, and Internet forums/groups. Methods such as newspaper articles, flyers, posters, and media articles or web-advertisements will be used to inform potential participants about the study (all material will be in German). Participants will be randomly assigned to either (1) a control group, in which they receive care as usual (CAU) and are given access to the internet intervention (Desiconnect) after a delay of 3 months (i.e., CAU/Wait list control group), or (2) a treatment group that may also use CAU and in addition immediately receives six-month access to the novel, internet-administered intervention (Desiconnect). Measurements are collected online at pre-treatment (baseline, T0), three months (T1), six months (T2), and nine months (T3).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression, Epilepsy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Desiconnect
Arm Type
Experimental
Arm Description
Desiconnect is an Internet-administered intervention developed for persons with epilepsy and elevated depression symptoms.
Arm Title
Care-as-Usual (CAU) / wait list
Arm Type
Active Comparator
Arm Description
In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Desiconnect three months post-baseline (i.e., wait list with respect to Desiconnect access).
Intervention Type
Behavioral
Intervention Name(s)
Desiconnect
Intervention Description
Desiconnect is an Internet intervention for persons with epilepsy and elevated depression. Content is continuously adapted to patients' concerns and needs. Techniques to overcome depression (e.g., cognitive restructuring, behavioral activation) and to cope with anxiety symptoms (e.g., exposure, role of avoidance, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Topics covered also include coping with epilepsy symptoms, identifying and coping with seizure auras and triggers, and the role of nutrition and exercise. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 180 days after registration.
Intervention Type
Other
Intervention Name(s)
CAU
Intervention Description
Care as Usual
Primary Outcome Measure Information:
Title
Severity of depressive symptoms, measured by Patient Health Questionnaire - 9 items (PHQ-9)
Description
Self-report depression symptom severity measure
Time Frame
Change from baseline to 3 months (also assessed at 6 and 9 months post-baseline)
Secondary Outcome Measure Information:
Title
NDDIE (Neurological Disorders Depression Inventory for Epilepsy)
Description
Epilepsy-specific self-report measure of depression symptom severity
Time Frame
Change from baseline to 3 months (also assessed at 6 and 9 months post-baseline)
Title
GAD-7 (Generalized Anxiety Disorder Questionnaire)
Description
Self-report anxiety symptom severity measure
Time Frame
Change from baseline to 3 months (also assessed at 6 and 9 months post-baseline)
Title
DASS-21 (Depression and Anxiety Scales)
Description
Self-report measure of anxiety, depression, and stress symptoms
Time Frame
Change from baseline to 3 months (also assessed at 6 and 9 months post-baseline)
Title
WSAS (Work and Social Adjustment Scale)
Description
Self-report measure of depression-related psychosocial impairment
Time Frame
Change from baseline to 3 months (also assessed at 6 and 9 months post-baseline)
Title
Subjective usefulness of the program
Description
Individually designed self-report items
Time Frame
Assessed at 3 and 6 months
Title
INEP (Inventory for the Assessment of Negative Effects of Psychotherapy)
Description
Adapted self-report measure assessing potential negative effects of the Internet intervention
Time Frame
Assessed at 3 and 6 months
Title
PESOS
Description
Self-report measure of epilepsy symptoms
Time Frame
Assessed at baseline, 3, 6, and 9 months
Title
LSSS (Liverpool Seizure Severity Scale)
Description
Self-report measure of epilepsy symptoms
Time Frame
Assessed at baseline, 3, 6, and 9 months
Title
QOLIE-10 (Health-related Quality of Life)
Description
Self-report measure of health-related quality of life
Time Frame
Assessed at baseline, 3, 6, and 9 months
Title
ESMS (Epilepsy Self-Management Scale)
Description
Self-report measure of epilepsy self-management practices
Time Frame
Assessed at baseline, 3, 6, and 9 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age at least 18 years diagnosis of active epilepsy (that is, at least one epileptic seizure within the past 10 years or taking antiseizure medicines within the past five years) current depressive disorder (either major depressive disorder or dysthymic disorder, as determined by telephone interview with the MINI Neuropsychiatric Interview) no current antidepressant medication, or current antidepressant medication but no changes in dosage for at least one month prior to study inclusion (medication changes after study inclusion are permitted, given the pragmatic design of the trial) currently at least moderate self-reported depressive symptom severity, as operationalized by a score of at least 10 on the PHQ-9, a cut-off score that has been well validated ability to speak and read German access to the internet and personal possession of an appropriate device on which the internet-based intervention can be used regularly (e.g., smartphone, computer, laptop) expressed motivation to participate in the trial and use an internet-based intervention to acquire skills and knowledge that may aid in the amelioration of depression symptoms Exclusion Criteria: current psychotherapy other known major psychiatric disorder, such as bipolar disorder, schizophrenia or another psychotic disorder, or borderline personality disorder (based on the MINI interview) acute suicidality (that is, intention or plan to commit suicide, as assessed with the respective module of the MINI interview) newly prescribed antidepressant medication or change in antidepressant medication dosage in month prior to study inclusion
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yvonne Nestoriuc, Ph.D.
Organizational Affiliation
University Medical Center Hamburg-Eppendorf (UKE), Department of Psychosomatic Medicine and Psychotherapy
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Medical Center Hamburg-Eppendorf (UKE), Department of Psychiatry and Psychotherapy
City
Hamburg
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Anonymized individual participant data shall be made available upon request for projects such as meta-analyses after completion of the study
Citations:
PubMed Identifier
28173780
Citation
Meyer B, Weiss M, Holtkamp M, Arnold S, Bruckner K, Schroder J, Scheibe F, Nestoriuc Y. Protocol for the ENCODE trial: evaluating a novel online depression intervention for persons with epilepsy. BMC Psychiatry. 2017 Feb 7;17(1):55. doi: 10.1186/s12888-017-1229-y.
Results Reference
background
PubMed Identifier
30802941
Citation
Meyer B, Weiss M, Holtkamp M, Arnold S, Bruckner K, Schroder J, Scheibe F, Nestoriuc Y. Effects of an epilepsy-specific Internet intervention (Emyna) on depression: Results of the ENCODE randomized controlled trial. Epilepsia. 2019 Apr;60(4):656-668. doi: 10.1111/epi.14673. Epub 2019 Feb 25.
Results Reference
result

Learn more about this trial

Evaluating a Novel Internet Intervention for Persons With Epilepsy and Depression

We'll reach out to this number within 24 hrs